
GH Stock Forecast & Price Target
GH Analyst Ratings
Bulls say
Guardant Health, a prominent player in liquid-based cancer diagnostics, is experiencing robust growth with a two-year revenue compound annual growth rate (CAGR) projected at +28% from 2023 to 2025, driven by the successful introduction of products like Shield and ongoing strength in colorectal cancer (CRC) and breast cancer applications. The company has also raised its annual revenue guidance for 2025, anticipating approximately 31% year-over-year growth, reflecting positive market demand and expansion into new monitoring applications. Additionally, Guardant's shares have demonstrated significant momentum, increasing by 136% year-to-date, which, along with its enhanced long-term revenue growth and margin assumptions, positions the company favorably in the market, potentially attracting larger institutional investments.
Bears say
Guardant Health's medium-term revenue guidance for its new Shield product has been perceived as underwhelming, contributing to a negative outlook for the company. The company reported an adjusted EBITDA loss of $45.5 million in Q3 2025, highlighting ongoing financial challenges. Additionally, potential setbacks related to regulatory approvals, reimbursement issues, and the timing of new product launches raise concerns about future growth and profitability.
This aggregate rating is based on analysts' research of Guardant Health Inc and is not a guaranteed prediction by Public.com or investment advice.
GH Analyst Forecast & Price Prediction
Start investing in GH
Order type
Buy in
Order amount
Est. shares
0 shares